Key facts
- It has raised $14.0M.
- Notable investors include Ludwig Institute for Cancer Research, Pebble Accelerator.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Pilatus Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Pilatus Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pilatus Biosciences
Operator of a biotechnology company designed to drive immuno-microenvironment reprogramming to combat cancer. The company specializes in drug discovery, cancer biology, translational medicine and clinical research, leveraging external expertise and fostering collaboration to rapidly build competitive pipelines for developing urgently needed medications that address unmet medical needs, enabling cancer patients to get better treatment.
- Sector
- Healthcare
- HQ
- Epalinges, Switzerland
- Founded
- 2022
- Website
- pilatusbio.com/
- Ownership
- Privately Held (backing)
Pilatus Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pilatus Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pilatus Biosciences in its N-PORT filings yet. We sweep new filings monthly.